DxS and Epigenomics Cross-License Technology for In Vitro Diagnostics
DxS Ltd. and Epigenomics AG announced that they have cross-licensed certain technologies enabling both companies to develop and commercialise in vitro diagnostic (IVD) products based on DNA methylation that utilise DxS' proprietary Scorpions technology.
The cross-licensing follows a strategic agreement signed by both companies in January 2008. Under the terms of this agreement, Epigenomics had obtained worldwide non-exclusive rights to DxS' Scorpions technology for R&D use and research kits, as well as an option to expand the license to the in vitro diagnostics field. In return, DxS received an option for a worldwide non-exclusive research and IVD license to certain Epigenomics IP covering the use of Scorpions technology for DNA methylation applications. Both companies have now executed their options as granted in last years agreement and have acquired the right to sub-license the respective licensed technologies.
Financial terms of the agreement were not disclosed.
Other news from the department business & finance
